Syndax Pharmaceuticals hit a setback after stopping work on a drug for lung disease.

Oct 13, 2026, 12:29 PM ETTrialRead the original at Benzinga

Bad for SNDX

Syndax will stop developing axatilimab for IPF after it missed the main trial goal. Its approved cGVHD use and other trials continue, but do not replace this lost path.

SNDX · Syndax Pharmaceuticals Inc.

AI read · Bad for SNDX

The AI's read

This removes one possible use for axatilimab and narrows its prospects. The drug remains approved for cGVHD, and other trials continue. Those facts soften the blow but do not erase the failed IPF study.

Get alerts for SNDX

Follow Syndax Pharmaceuticals Inc. (SNDX) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for SNDX

Free on the App Store and Google Play, or on the web.